Antônio A Beck, Letícia B Paz, Maria I Frank, Roberta C F Pereira, Flávio D De La Côrte
{"title":"Lameness improvement in horses with distal tarsal pain after intra-articular injection of botulinum neurotoxin type A.","authors":"Antônio A Beck, Letícia B Paz, Maria I Frank, Roberta C F Pereira, Flávio D De La Côrte","doi":"10.2460/ajvr.24.10.0294","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the effect of IA injections of botulinum toxin type A (BoNT-A) in horses with chronic, naturally occurring distal tarsal osteoarthritis.</p><p><strong>Methods: </strong>9 horses were selected after physical and radiographic assessments. Horses also underwent an objective lameness examination and were included if they had a hindlimb impact lameness (Pmin ≥ 3 mm), which positively responded (≥ 50%) to the tarsometatarsal and centrodistal joints' anesthetic block. Horses randomly received an intra-articular injection of BoNT-A or an equivalent volume of saline solution. Horses were reevaluated at postinjection days (PIDs) 1, 7, 15, 30, 60, 90, 120, 150, and 180. Success criteria included a decrease in Pmin (≤ 3 mm) or an abolishment of lameness on the baseline lame limb with lameness shifting to the contralateral limb. A percentage of lameness improvement was calculated for all horses at all timepoints.</p><p><strong>Results: </strong>5 horses were included in the BoNT-A group, whereas 4 individuals were allocated in the placebo group. A significant improvement (P < .05) was observed in horses from the BoNT-A group when compared to placebo at PIDs 90, 120, 150, and 180. Two of 5 horses (40%) from the BoNT-A group had an absolute improvement (100%) in lameness at all the timepoints. Higher percentages of lameness improvement were observed at PID 60.</p><p><strong>Conclusions: </strong>The results of this study suggest that the intra-articular injection with 50 U of BoNT-A was effective in reducing lameness in horses with distal tarsal osteoarthritis, mainly 90 days after injection.</p><p><strong>Clinical relevance: </strong>Botulinum toxin type A can be considered as an option for managing horses with chronic osteoarthritis.</p>","PeriodicalId":7754,"journal":{"name":"American journal of veterinary research","volume":" ","pages":"1-7"},"PeriodicalIF":1.3000,"publicationDate":"2025-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American journal of veterinary research","FirstCategoryId":"97","ListUrlMain":"https://doi.org/10.2460/ajvr.24.10.0294","RegionNum":3,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"VETERINARY SCIENCES","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: To evaluate the effect of IA injections of botulinum toxin type A (BoNT-A) in horses with chronic, naturally occurring distal tarsal osteoarthritis.
Methods: 9 horses were selected after physical and radiographic assessments. Horses also underwent an objective lameness examination and were included if they had a hindlimb impact lameness (Pmin ≥ 3 mm), which positively responded (≥ 50%) to the tarsometatarsal and centrodistal joints' anesthetic block. Horses randomly received an intra-articular injection of BoNT-A or an equivalent volume of saline solution. Horses were reevaluated at postinjection days (PIDs) 1, 7, 15, 30, 60, 90, 120, 150, and 180. Success criteria included a decrease in Pmin (≤ 3 mm) or an abolishment of lameness on the baseline lame limb with lameness shifting to the contralateral limb. A percentage of lameness improvement was calculated for all horses at all timepoints.
Results: 5 horses were included in the BoNT-A group, whereas 4 individuals were allocated in the placebo group. A significant improvement (P < .05) was observed in horses from the BoNT-A group when compared to placebo at PIDs 90, 120, 150, and 180. Two of 5 horses (40%) from the BoNT-A group had an absolute improvement (100%) in lameness at all the timepoints. Higher percentages of lameness improvement were observed at PID 60.
Conclusions: The results of this study suggest that the intra-articular injection with 50 U of BoNT-A was effective in reducing lameness in horses with distal tarsal osteoarthritis, mainly 90 days after injection.
Clinical relevance: Botulinum toxin type A can be considered as an option for managing horses with chronic osteoarthritis.
期刊介绍:
The American Journal of Veterinary Research supports the collaborative exchange of information between researchers and clinicians by publishing novel research findings that bridge the gulf between basic research and clinical practice or that help to translate laboratory research and preclinical studies to the development of clinical trials and clinical practice. The journal welcomes submission of high-quality original studies and review articles in a wide range of scientific fields, including anatomy, anesthesiology, animal welfare, behavior, epidemiology, genetics, heredity, infectious disease, molecular biology, oncology, pharmacology, pathogenic mechanisms, physiology, surgery, theriogenology, toxicology, and vaccinology. Species of interest include production animals, companion animals, equids, exotic animals, birds, reptiles, and wild and marine animals. Reports of laboratory animal studies and studies involving the use of animals as experimental models of human diseases are considered only when the study results are of demonstrable benefit to the species used in the research or to another species of veterinary interest. Other fields of interest or animals species are not necessarily excluded from consideration, but such reports must focus on novel research findings. Submitted papers must make an original and substantial contribution to the veterinary medicine knowledge base; preliminary studies are not appropriate.